Goldman Sachs' Asad Haider on the stocks impacted by new heart attack prevention drug trials
Asad Haider, Goldman Sachs, joins 'Closing Bell Overtime' to talk new heart attack prevention drug trials and which companies are poised to benefit from the drugs. Note: Clip originally aired 4/27/2026.
Asad Haider, Goldman Sachs, joins 'Closing Bell Overtime' to talk new heart attack prevention drug trials and which companies are poised to benefit from the drugs. Note: Clip originally aired 4/27/2026.
What's Your Reaction?
:max_bytes(150000):strip_icc()/GettyImages-2187410260-5afe56694791404f99c253dd8d5abe6a.jpg?#)
